{
  "evidence": [{
    "id": "civic:eid2997",
    "type": "evidence",
    "description": "Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test",
    "direction": "supports",
    "evidence_level":"civic.evidence_level:A",
    "proposition": "proposition:001",
    "evidence_sources": ["source:001"],
    "contributions": ["contribution:001"],
    "strength": "civic.trust_rating:5_star"
  }],
  "propositions": [
    {
      "id": "proposition:001"
      "type": "therapeutic_response_proposition",
      "vrsatile_descriptor": "civic:33",
      "therapy": "ncit:C66940",
      "disease_context": "ncit:C2926",
      "predicate": "predicts_sensitivity_to",
      "variation_origin": "somatic",
    }
  ],
  "vrsatile_descriptors": [
    {
      "id": "civic:33",
      
    }
  ],
  "therapies": [

  ],
  "diseases": [

  ],
  "evidence_sources": [
    {
      "id": "pmid:23982599",
      "label": "Dungo et al., 2013, Drugs",
      "description": "Afatinib: first global approval.",
      "xrefs": []
    }
  ],
  "contributions": [

  ],
  "agents": [

  ]
}
